È®Á¤ ¿¬»ç

Andreas Möller, Professor, Director, JC STEM Lab of Personalized Cancer Medicine, Prince of Wales Hospital, Chinese University of Hong Kong

Banishree Saha, Associate Director, Early Clinical Development, Takeda Pharmaceuticals

Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS)

Han Wei Hou, Associate Professor, School of Mechanical and Aerospace Engineering, Nanyang Technological University Singapore

Hang Hubert Yin, Professor, Tsinghua University

Mei He, Associate Professor, University of Florida -- Conference Chairperson

Nao Nishida-Aoki, Assistant Professor, Waseda Institute for Advanced Studies (WIAS), Waseda University

Noah Malmstadt, Professor, Mork Family Dept. of Chemical Engineering & Materials Science, University of Southern California

Takahiro Ochiya, Distinguished Professor, Tokyo Medical University
ÄÁÆÛ·±½º °³¿ä
SelectBIO´Â 2025³â 10¿ù 6ÀÏ-7ÀÏ, È£ÅÚ ´ÖÄÚ ³ª¸®Å¸(³ª¸®Å¸ ±¹Á¦ °øÇ× ±Ùó)¿¡¼ Extracellular Vesicles/Exosomes Asia 2025¸¦ °³ÃÖÇÕ´Ï´Ù.
ÄÁÆÛ·±½º´Â ´ÙÀ½ 2°³ Æ®·¢À¸·Î ±¸¼ºµË´Ï´Ù.
-
Lab-on-a-Chip, Microfluidics, Organoids and Organ-on-a-Chip Asia 2025
-
Extracellular Vesicles/Exosomes Asia 2025
Âü°¡ÀÚ¿Í Àü½Ã±â¾÷Àº µÎ Æ®·¢¿¡ Ç® ¾×¼¼½ºÇÏ¿© °úÇÐÀû ±³·ù¿Í ³×Æ®¿öÅ·À» ±Ø´ëÈÇÒ ¼ö ÀÖ½À´Ï´Ù.
SelectBIOÀÇ Extracellular Vesicles/Exosomes Asia 2025´Â Ç÷θ®´Ù ´ëÇб³ÀÇ Mei He ±³¼ö°¡ ÀÇÀåÀ» ¸ÃÀ¸¸ç, ¾Æ½Ã¾ÆÀÇ Çмú °ü°èÀÚ, ¾÷°è/±â¾÷ °ü°èÀÚ°¡ ÇÑÀÚ¸®¿¡ ¸ðÀÔ´Ï´Ù. ÀÌ ÄÁÆÛ·±½ºÀÇ ¿¬»ç´Â EV ¿¬±¸ Åø °³¹ß¿¡¼ ÀÎÇÁ¶ó¿Í Çõ½ÅÀ» Á¦°øÇÏ´Â Çмú±â°ü, ±â¾÷, ±â¼ú/Åø/°èÃø ±â±â ±â¾÷ÀÔ´Ï´Ù.
¿¬±¸¡¤Áø´Ü¡¤Ä¡·áÀÇ °üÁ¡À¸·ÎºÎÅÍ ¾Æ½Ã¾ÆÀÇ ¼¼Æ÷¿Ü¼ÒÆ÷(EV)/¿¢¼ÒÁ»¿¡ ´ëÇÑ ³ôÀº °ü½ÉÀ» °¨¾ÈÇÏ¿© ÀÌ ÄÁÆÛ·±½º¿¡¼´Â ÀÌ ºÐ¾ßÀÇ ´Ù¾çÇÑ °ü°èÀÚ°¡ ÇÑÀÚ¸®¿¡ ¸ð¿© 2Àϰ£ ÁýÁßÀûÀÎ °úÇÐ ÇÁ·¹Á¨Å×À̼Ç, Á¦Ç° ½Ã¿¬, Çлý ¹× Æ÷½ºÆ® ´ÚÅÍÀÇ Æ÷½ºÅÍ ¹ßÇ¥ µîÀ» ÅëÇØ ¿¬±¸ÀÇ ¼³¸í°ú ÀüÆÄ¸¦ µµ¸ðÇÕ´Ï´Ù.
Æ÷½ºÅÍ ¹ßÇ¥ÀÇ ÃÊ·Ï
ÄÁÆÛ·±½º¿¡ Âü°¡ÇÏ¸é¼ Æ÷½ºÅÍ·Î ¿¬±¸¸¦ ¹ßÇ¥ÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ½É»ç¿ëÀ¸·Î ÃÊ·Ï Á¦ÃâÀÌ ÇʼöÀÔ´Ï´Ù.
Æ÷½ºÅÍ ¹ßÇ¥ Á¦Ãâ ±âÇÑ : 2025³â 9¿ù 15ÀÏ
ÄÁÆÛ·±½º ¾ÆÁ¨´Ù ÅäÇÈ
-
Biomarker Content of Extracellular Vesicles and Role for Diagnostics
¼¼Æ÷¿Ü¼ÒÆ÷(EV)¿¡¼ ¹ÙÀÌ¿À¸¶Ä¿ ÄÁÅÙÃ÷¿Í Áø´ÜÀÇ ¿ªÇÒ -
Disease Areas where EV-based Diagnostics Being Developed
°³¹ßÁßÀÎ EV ±â¹Ý Áø´ÜÀÇ Áúȯ ¿µ¿ª -
Extracellular Vesicles (EVs): Therapeutic and Drug Delivery Potential
¼¼Æ÷¿Ü¼ÒÆ÷(EV) : Ä¡·á¿Í ¾à¹°Àü´ÞÀÇ °¡´É¼º -
Single Extracellular Vesicle (EV) Analysis by Flow Cytometry
À¯¼¼Æ÷ºÐ¼®¿¡ ÀÇÇÑ ´ÜÀÏ ¼¼Æ÷¿Ü¼ÒÆ÷(EV) ºÐ¼® -
Technologies for Engineering EVs for Therapeutics, Drug Delivery
Ä¡·á¡¤¾à¹°Àü´Þ¿ë EV ¿£Áö´Ï¾î¸µ ±â¼ú -
Technologies for the Isolation, Characterization and Study of Extracellular Vesicles (EVs)-Exosomes
¼¼Æ÷¿Ü¼ÒÆ÷(EV)/¿¢¼ÒÁ»ÀÇ ´Ü¸®, Ư¼º Æò°¡, ¿¬±¸ ±â¼ú
½ºÆù¼¡¤Àü½Ã ±âȸ
ÀÚ¼¼ÇÑ »çÇ×Àº(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀ̼ÇÀ¸·Î ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù.
Andreas Möller, Professor, Director, JC STEM Lab of Personalized Cancer Medicine, Prince of Wales Hospital, Chinese University of Hong Kong
Andreas Möller Biographical Sketch
Professor Andreas Möller is a trained biochemist and cancer biologist, with >20 years¡¯ experience in cancer research. He is Professor in the Faculty of Medicine at the Chinese University of Hong Kong, supported by the prestigious Global STEM Professor fellowship. In addition, he is the Director of the Jockey Club Laboratory of Precision Cancer Medicine at the Li Ka Shing Institute of Health Sciences. Previously, between 2012 and 2023, he led the Tumour Microenvironment Laboratory at the QIMRB Medical Research Institute, Brisbane, Australia. Professor Möller has a strong background in cancer cell biology, extracellular vesicle (EV) biology, hypoxia research, cancer metastasis and cancer immunology. He is Member of the Board of Directors of the International Society of Extracellular Vesicles since 2022, and since 2024 elected Executive Chair for Meetings and Programs as well as one of the founders and Executive Board Member of the Asia Pacific Societies of Extracellular Vesicles.
Banishree Saha, Associate Director, Early Clinical Development, Takeda Pharmaceuticals
Banishree Saha Biographical Sketch
Dr. Banishree Saha serves as the Associate Director and Analytical Lead for Translational Biomarker Assays at Takeda Pharmaceuticals in Cambridge, MA. She is instrumental in advancing biomarker assay development and spearheading innovative research in gastrointestinal and liver diseases. Renowned for her expertise in extracellular vesicles, especially exosomes, Dr. Saha has made substantial contributions to understanding the role of microRNA cargo in immune responses during liver injury. Her extensive experience in academia and the pharmaceutical industry allows her to significantly influence the field of liver biology and translational research, devising new therapeutic strategies for liver-related ailments.
Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS)
Danilo Tagle Biographical Sketch
Dan Tagle is Director of the Office of Special Initiatives at NCATS where he many coordinates efforts towards development of disruptive technologies in translational research. He obtained his Ph.D. in Molecular Biology and Genetics from Wayne State University School of Medicine. He was an NIH National Research Service Award postdoctoral fellow in Human Genetics at the University of Michigan. He has served on numerous committees, advisory boards, and editorial boards. He has authored many scientific publications and has garnered numerous awards, including more recently the Roscoe O. Brady Award for Innovation and Accomplishment, and the Henry J. Heimlich Award for Innovative Medicine.
Han Wei Hou, Associate Professor, School of Mechanical and Aerospace Engineering, Nanyang Technological University Singapore
Han Wei Hou Biographical Sketch
Dr. Han Wei Hou is an Associate Professor at the School of Mechanical and Aerospace Engineering (MAE), and Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University Singapore (NTU). He is also an Adjunct Senior Research Scientist at Tan Tock Seng Hospital (TTSH), and currently serves as the Assistant Chair (Students) at MAE. Dr. Hou received his BEng (First Class Hons) and PhD degree in Biomedical Engineering at the National University of Singapore in 2008 and 2012, respectively. Upon graduation, he did his postdoctoral training at Massachusetts Institute of Technology (USA), and subsequently joined LKCMedicine as the inaugural LKCMedicine Postdoctoral Fellow in 2014. He started his research group at NTU (BioMicroSystems Laboratory, www.hwhoulab.com) in 2018 and his research interests include microfluidics blood diagnostics, organ-on-chips, and cell-based biomanufacturing. He has authored over 60 peer-reviewed journal publications and filed 15 patents/patent applications. His recent research awards and accolades include World's Top 2% Scientists (By Stanford University) (2023, 2024), International Academy of Medical and Biological Engineering (IAMBE) Early Career Award (2022), NTU College of Engineering Research - Young Faculty Special Mention (2022), and International Society for Advancement of Cytometry (ISAC) Innovators (2021).
Hang Hubert Yin, Professor, Tsinghua University
Hang Hubert Yin Biographical Sketch
Professor Hang Hubert Yin was born in Beijing in 1976. After studying for a bachelor's degree at Peking University, he received his PhD from Yale University in 2004 under the supervision of Professor Andrew Hamilton and then spent a post-doctoral period at the University of Pennsylvania School of Medicine with Professor William DeGrado. In 2018, Professor Yin joined the School of Pharmaceutical Sciences at Tsinghua University as a founding Deputy Dean. Prior to joining Tsinghua, he was a tenured faculty member of the University of Colorado Boulder. His research interests lie at the interface of chemistry, biology, and engineering with particular focuses on structure-based drug design, extracellular vesicles, cell signaling biochemistry, biotechnology development, and membrane protein simulations. Professor Yin is a recipient of many accolades for his research in chemical biology and drug discovery, including the Wu Jieping-Paul Janssen Medical & Pharmaceutical Award, American Chemical Society David W. Robertson Award for Excellence in Medicinal Chemistry, OKeanos-CAPA Senior Investigator Award, National Science Fund for Distinguished Young Scholars, Beijing Outstanding Young Scientist, CAPA Distinguished Junior Faculty Award, NSF CAREER Award, AACR Gertrude B. Elion Cancer Research Award, Sidney Kimmel Scholars Award, and HHMI Collaborative Innovation Award among others. Professor Yin¡¯s is currently serving as a member of the Academic Committee of Tsinghua University, a Senior Advisor to the ISEV Board, the Editor-in-Chief of Bioorganic and Medicinal Chemistry Letters, and a Deputy Editor of the Journal of Extracellular Vesicles.
Mei He, Associate Professor, University of Florida
Mei He Biographical Sketch
Dr. He was named as the senior member of the National Academy of Inventors in 2023. Dr. He is also the Board advisor of Gordon and Betty Moore Foundation, Chair of American Association of Pharmaceutical Scientists (AAPS) scientific programing committee, and Chair of American Association of Extracellular Vesicles (AAEV) scientific programing committee, the Editorial Board Advisor for journal of Pharmaceutics and Lab on Chip (RSC). Dr. He research brings in novel solutions for therapeutic development, by leveraging broad research outcomes from her research lab including surface molecular engineering, cargo loading and transfection, gene editing and multi-omic sequencing. Her recent publications in Science Translational Medicine introduced a novel gene therapy approach via EV-based CRISPR editing for restoring hearing loss in vivo, which presents great potential for clinical translation on treating progressive hearing loss diseases caused by genetic mutations, especially for newborn babies with minimized toxicity. Dr. He received the NIH Maximizing Investigator¡¯s Research Award for Early-Stage Investigators in 2019, and the LOC Emerging Investigator Award by the Royal Society of Chemistry.
Nao Nishida-Aoki, Assistant Professor, Waseda Institute for Advanced Studies (WIAS), Waseda University
Nao Nishida-Aoki Biographical Sketch
Nao Nishida-Aoki is an Assistant Professor at Waseda Institute for Advanced Study (WIAS) since 2022, focusing on extracellular vesicle (EV)-mediated communication between cancer and host cells within physiological tumor microenvironments. She received her Ph.D. from Kyoto University in 2014, studying transcriptional regulation in stress-tolerant yeast. Then she joined National Cancer Center Research Institute (Tokyo, Japan) as a postdoctoral fellow, demonstrating the therapeutic potential of targeting cancer-derived EVs in breast cancer metastasis. At Fred Hutchinson Cancer Research Center (Seattle, WA, USA), she explored molecular mechanisms of cancer-host cell interactions in a physiological tissue context, utilizing organotypic tumor tissue slices and in vitro tumor-associated macrophage polarization model. She was supported by JSPS research fellowships during her training and currently funded by KAKENHI and several private foundations. She has served as a committee member of the Japanese Society for Extracellular Vesicles (JSEV) since 2022.
Noah Malmstadt, Professor, Mork Family Dept. of Chemical Engineering & Materials Science, University of Southern California
Noah Malmstadt Biographical Sketch
Noah Malmstadt is Professor at the University of Southern California. He received a BS in Chemical Engineering from Caltech and a PhD in Bioengineering from the University of Washington. Following postdoctoral work at UCLA, he joined the Mork Family Department of Chemical Engineering and Materials Science at USC in 2007. Malmstadt is the recipient of a 2012 Office of Naval Research Young Investigator award. His research focuses on microfluidic strategies to facilitate material fabrication and biophysical analysis. He has pioneered the integration of ionic liquids as solvents in droplet microreactors and the application of microfluidic systems to synthesizing biomimetic cell membranes. Microfluidic analytical techniques he has developed include methods for measuring the permeability of cell membranes to druglike molecules and techniques for measuring ionic currents through membrane proteins.
Takahiro Ochiya, Distinguished Professor, Tokyo Medical University
Takahiro Ochiya Biographical Sketch
Dr. Takahiro Ochiya was a Chief of Division of Molecular and Cellular Medicine at the National Cancer Center Research Institute, Tokyo since 2011 and he is currently appointed as professor of Tokyo Medical University (since 2018). After he got Ph.D. in 1988 in Osaka University and then went to do a post-doc at La Jolla Cancer Research (The SF Burnham Institute for Medical Research), CA, USA. Dr. Ochiya¡¯s lab focuses the development of novel animal models, methods, and strategies to study cancer development and metastasis. Especially, current focuses are siRNA- and microRNA-based diagnosis and therapy of cancer. He is also one of the top scientist in the study of extracellular vesicles (EV). Dr. Ochiya is awarded as web of science top 1% highly cited researchers (HCR) 2019, 2020, 2021, and 2022 and carries President of Japanese Society of Extracellular Vesicles (JSEV) since 2014.
½É»ç¿¡ Åë°úÇÏ¸é Æ÷½ºÅÍ ¹ßÇ¥¿¡ ÇÊ¿äÇÑ Á¤º¸°¡ ¸ðµÎ Á¦°øµË´Ï´Ù.
ÃÊ·Ï ³»¿ë
- ¿µ¹®
- »ïÀÎĪ
- ŸÀÌÆ², ÀúÀÚ¸í, ¼Ò¼ÓÀ» ¸í±â
- ¿µ¾î·Î 100-200 words
- ȸÀÇ·Ï ¹× À¥»çÀÌÆ® °ÔÀç°¡ °¡´É
- ÄÁÆÛ·±½º ÁÖÁ¦¿¡ °ü·Ã
¾ÆÁ¨´Ù ÅäÇÈ
- Biomarker Content of Extracellular Vesicles and Role for Diagnostics
¼¼Æ÷¿Ü¼ÒÆ÷(EV)¿¡¼ ¹ÙÀÌ¿À¸¶Ä¿ ÄÁÅÙÃ÷¿Í Áø´ÜÀÇ ¿ªÇÒ - Disease Areas where EV-based Diagnostics Being Developed
°³¹ßÁßÀÎ EV ±â¹Ý Áø´ÜÀÇ Áúȯ ¿µ¿ª - Extracellular Vesicles (EVs): Therapeutic and Drug Delivery Potential
¼¼Æ÷¿Ü¼ÒÆ÷(EV) : Ä¡·á¿Í ¾à¹°Àü´ÞÀÇ °¡´É¼º - Single Extracellular Vesicle (EV) Analysis by Flow Cytometry
À¯¼¼Æ÷ºÐ¼®¿¡ ÀÇÇÑ ´ÜÀÏ ¼¼Æ÷¿Ü¼ÒÆ÷(EV) ºÐ¼® - Technologies for Engineering EVs for Therapeutics, Drug Delivery
Ä¡·á¡¤¾à¹°Àü´Þ¿ë EV ¿£Áö´Ï¾î¸µ ±â¼ú - Technologies for the Isolation, Characterization and Study of Extracellular Vesicles (EVs)-Exosomes
¼¼Æ÷¿Ü¼ÒÆ÷(EV)/¿¢¼ÒÁ»ÀÇ ´Ü¸®, Ư¼º Æò°¡, ¿¬±¸ ±â¼ú
ÀúÀÛ±Ç
ÃÊ·Ï ³»¿ë¿¡ ´ëÇØ¼´Â ¹ßÇ¥ÀÚ/ÀúÀÚ°¡ ¸ðµç Ã¥ÀÓÀ» Áö¸ç, °øÀúÀÚ Àü¿øÀÌ ÀÌ ³»¿ëÀ» ÀνÄÇϰí ÀÖ´Â °ÍÀ¸·Î °¡Á¤ÇÕ´Ï´Ù. °æ·Â, ¿ä¾à, ÃÊ·ÏÀº À¥»çÀÌÆ® ¹× ÄÁÆÛ·±½º ÀÚ·á·Î »ç¿ëµÉ ¼ö ÀÖ½À´Ï´Ù.
2025³â 10¿ù 7ÀÏ
08:00
Ozora Room
Coffee, Tea and Networking in the Exhibit Hall
Àü½ÃȦ¿¡¼ÀÇ Ä¿ÇÇ¡¤Æ¼¡¤³×Æ®¿öÅ·
2025³â 10¿ù 7ÀÏ
09:00
Tsuru
Chairperson's Opening Remarks
ÀÇÀå °³È¸»ç

Mei He, Associate Professor, University of Florida, United States of America
Chairperson's Welcome and Introduction to the Conference and Topics Addressed
ÀÇÀåÀÇ È¯¿µ°ú ÄÁÆÛ·±½º ¼Ò°³, ÄÁÆÛ·±½º¿¡¼ ´Ù·ç¾îÁö´Â ÅäÇÈ
2025³â 10¿ù 7ÀÏ
09:15
Tsuru

Andreas Möller, Professor, Director, JC STEM Lab of Personalized Cancer Medicine, Prince of Wales Hospital, Chinese University of Hong Kong
Translation of Extracellular Vesicles from Bench to Bedside
¼¼Æ÷¿Ü¼ÒÆ÷(EV)ÀÇ ±âÃÊ ¿¬±¸·ÎºÎÅÍ ÀÓ»ó(B2B)À¸·ÎÀÇ ÀÀ¿ë
Extracellular vesicles (EVs) present a huge, yet largely untapped resource for disease diagnostics and therapeutics. While significant advancements have been made in bench-based investigations, these have largely not yet been successfully translated to clinical or commercial applications. In the context of cancer, the evaluation of EV cargo composition changes allowed us to develop highly sensitive, liquid biopsy diagnostic and prognostic biomarkers. In this presentation, the translational work, including the validation in retrospective patient cohorts and prospective trials will be discussed. Some of the technical and logistic challenges faced when transitioning bench methods to bedside applications, and their implementation into a hospital setting, will be highlighted.
2025³â 10¿ù 7ÀÏ
09:45
Tsuru

Hang Hubert Yin, Professor, Tsinghua University, China
Exploring the Frontiers of EV Research by Bridging Basic Science and Biomedical Applications
±âÃʰúÇаú ¹ÙÀÌ¿À¸ÞµðÄà ÀÀ¿ëÀÇ Áß°³¿¡ ÀÇÇØ EV ¿¬±¸ÀÇ ÃÖÀü¼± ޱ¸
We have been focusing on the mechanistic studies of extracellular vesicles (EVs) by investigating their roles in innate immunity and cell-cell communications. For example, we have found that transport of ODN and Cdc42 from TLR9-activated macrophages to naïve cells via EVs exerts synergetic effects in propagation of the intracellular immune response, suggesting a general mechanism of EV-mediated uptake of pathogen-associated molecular patterns. Furthermore, these EVs may render an emerging disease biomarker that possesses tremendous theranostic potential. Nonetheless, the secretion of EVs cannot be monitored using traditional detection methods due to their small sizes. We developed an innovative strategy to target and capture EVs from various metastatic cancers using rationally designed peptide probes that recognize highly curved surface of these disease related EVs. These peptide probes also provide tools to selectively target cancer cells with specific lipid compositions and distributions, laying the foundation for further development of the next-generation of diagnostics and prognostics.
2025³â 10¿ù 7ÀÏ
10:15
Tsuru

Han Wei Hou, Associate Professor, School of Mechanical and Aerospace Engineering, Nanyang Technological University Singapore
Label-Free Microfluidics Technologies for Extracellular Vesicles Isolation
¼¼Æ÷¿Ü¼ÒÆ÷(EV) ºÐ¸®¿¡ ´ëÇÑ ¶óº§ ÇÁ¸® ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¼ú
Emerging biomarkers including extracellular vesicles (EVs) and microRNAs have shown great potential in blood-based diagnostics. However their detection is often confounded by delayed blood processing and cellular contamination due to non-standardized centrifugation practices which may cause large variations in plasma quality. Conventional EV isolation methods using ultracentrifugation, size-exclusion chromatography (SEC) and tangential flow filtration (TFF) are manual, time-consuming and require plasma as input sample. In this talk, I will highlight the development of several label-free microfluidic tools from our lab for EV sample preparation. We will first present a high throughput (~10 mins/per mL of whole blood) and gentle microfluidic sorting technology (ExoArc) for single-step plasma extraction from whole blood. With a size cut-off of 500 nm based on particle inertial focusing effects, ExoArc-isolated plasma is completely cell-free, platelet-free and highly enriched in EVs. When coupled with SEC, this centrifugation-free workflow (< 1 hr) greatly improves EV yield while reducing formation of EV aggregation and platelet-derived EVs as compared to ultracentrifugation. To address the bottleneck of protein contamination, we also developed a microfluidic SEC device (µSEC) integrated with an on-chip nanoliter sample plug injection to separate EVs from plasma proteins under continuous flow. We envision that ¥ìSEC system can be readily automated and integrated with ExoArc and downstream EV detection or assays for real time monitoring tool in EVs manufacturing or EV-based clinical applications.
2025³â 10¿ù 7ÀÏ
10:45
Ozora Room
Mid-Morning Coffee and Tea Break and Networking in the Exhibit Hall
Àü½ÃȦ¿¡¼ÀÇ ¿ÀÀü Ä¿ÇÇ¡¤Æ¼ºê·¹ÀÌÅ©, ³×Æ®¿öÅ·
2025³â 10¿ù 7ÀÏ
11:30
Tsuru
Keynote Presentation
±âÁ¶ °¿¬

Takahiro Ochiya, Distinguished Professor, Tokyo Medical University, Japan
Study of Common Mechanisms of Cancer EV Secretion
¾Ï EV ºÐºñÀÇ °øÅë ¸ÞÄ¿´ÏÁòÀÇ ¿¬±¸
Extracellular vesicles (EVs) are involved in intercellular communication during cancer progression; thus, elucidating the mechanism of EV secretion in cancer cells will contribute to the development of an EV-targeted cancer treatment. However, the common mechanisms of biogenesis of EVs in cancer cells is not fully understood. Here we present microRNA library screening allowed elucidating some specific microRNAs which are significantly involved in cancer EVs secretion and their molecular targets are contributed to cancer progression such as metastasis and drug resistance.
2025³â 10¿ù 7ÀÏ
12:00
Ozora Room
Networking Lunch in the Exhibit Hall -- Network with Colleagues, View Posters and Engage with Exhibitors
Àü½ÃȦ¿¡¼ÀÇ ³×Æ®¿öÅ· ·±Ä¡ -- µ¿·á¿ÍÀÇ ³×Æ®¿öÅ·, Æ÷½ºÅÍ ¿¶÷, Àü½Ã±â¾÷°úÀÇ ±³·ù
**Japanese Bento Lunch**
**ÀÏ½Ä µµ½Ã¶ô**
2025³â 10¿ù 7ÀÏ
13:30
Tsuru

Banishree Saha, Associate Director, Early Clinical Development, Takeda Pharmaceuticals, United States of America
Extracellular Vesicles as Biomarkers: A New Frontier in Medical Diagnostics
¹ÙÀÌ¿À¸¶Ä¿·Î¼ÀÇ ¼¼Æ÷¿Ü¼ÒÆ÷(EV) : ÀÇ·á Áø´ÜÀÇ ´ºÇÁ·ÐƼ¾î
Extracellular Vesicles (EVs) represent an exciting frontier in medical diagnostics, offering unique potential as biomarkers for various diseases, including liver disease. These nano-sized vesicles, secreted by cells, carry proteins, lipids, and nucleic acids that reflect the physiological state of their parent cells. Emerging research highlights their role in intercellular communication and their potential for disease detection and monitoring. Advancements in EV isolation and characterization techniques have demonstrated their application in diagnosing conditions such as cancer, neurological disorders, infectious diseases, and liver disease. With their non-invasive nature and ability to support early detection, EV-based diagnostics align closely with the goals of precision medicine. This discussion will explore the advancements, challenges, and future directions in integrating EV-based diagnostics into clinical practice to enhance early, accurate, and efficient disease detection.
2025³â 10¿ù 7ÀÏ
14:00
Tsuru

Nao Nishida-Aoki, Assistant Professor, Waseda Institute for Advanced Studies (WIAS), Waseda University, Japan
Spatiotemporal Visualization of Extracellular Vesicle Transfer at Early Metastatic Niche
ÀüÀÌ Ãʱ⠴ÏÄ¡¿¡¼ ¼¼Æ÷¿Ü¼ÒÆ÷(EV) À̵¿ÀÇ ½Ã°ø°£ °¡½ÃÈ
Cancer cells actively reprogram surrounding non-malignant cells into tumor-supportive phenotypes to initiate metastatic growth in distant organs. To investigate the role of cancer extracellular vesicles (EVs) in this early microenvironmental remodeling, we established organotypic ex vivo models of breast cancer metastasis using organotypic tissue slice cultures (TSCs) from mouse brain and lungs. By combining these models with two-photon microscopy and HaloTag-labeled EVs, we achieved real-time visualization of EV secretion within native tissue architecture. We observed heterogeneous EV distributions and organ-specific uptake by different cell populations. These findings reveal selective EV targeting mechanisms potentially contributing to organ tropism during metastatic colonization. This approach provides a powerful platform to dissect the spatiotemporal dynamics of EV-mediated microenvironment formation in physiologically relevant contexts.
2025³â 10¿ù 7ÀÏ
14:30
Tsuru

Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America
Site-specific Targeting for Drug Delivery and EV Therapeutics in Regenerative Medicine
Àç»ýÀÇ·á¿¡¼ ¾à¹°Àü´Þ¡¤EV ÀǾà¿ë ºÎÀ§ ƯÀÌÀû Ÿ°ÙÆÃ
2025³â 10¿ù 7ÀÏ
15:00
Ozora Room
Mid-Afternoon Coffee and Tea Break in the Exhibit Hall and Networking with Exhibitors and Poster Presenters
Àü½ÃȦ¿¡¼ÀÇ ¿ÀÈÄ Ä¿ÇÇ¡¤Æ¼ºê·¹ÀÌÅ©, Àü½Ã±â¾÷ ¹× Æ÷½ºÅÍ ¹ßÇ¥ÀÚ¿ÍÀÇ ³×Æ®¿öÅ·
2025³â 10¿ù 7ÀÏ
15:30
Tsuru
Keynote Presentation
±âÁ¶ °¿¬

Mei He, Associate Professor, University of Florida, United States of America
Bioengineering of Extracellular Vesicles for Precision Medicine
Á¤¹ÐÀÇ·á¿ë ¼¼Æ÷¿Ü¼ÒÆ÷(EV)ÀÇ ¹ÙÀÌ¿À¿£Áö´Ï¾î¸µ
Extracellular vesicles (EVs) are nanosized membrane particles, which have been recognized as the ideal alternative for drug delivery and therapeutic development. EVs are secreted from live cells with minimal toxicity and immunogenicity to in vivo systems, and enable the delivery of a variety of large size payloads including CRISPR Cas9/sgRNA RNP complexes. Recent discoveries also showed the strong ability of EVs to cross difficult biological barriers. However, the heterogeneity of EV surface presentation and diverse molecular makeup make them difficult to study. We reported novel molecular engineering and microfluidic approaches for surface modification, intravesicular payload loading, and biomarker discovery. Particularly, the CRISPR gene editing, and AI directed extracellular vesicle surface engineering overcome the current challenge in tissue targeting specificity in the field, which could lead the promise for developing next-generation precision therapeutics and gene therapy.
2025³â 10¿ù 7ÀÏ
16:00
Tsuru
Panel Discussion Chaired by Professor Mei He, Conference Chairperson
ÆÐ³Î µð½ºÄ¿¼Ç(Mei He ±³¼ö°¡ ÄÁÆÛ·±½º ÀÇÀå)
**Emerging Trends in Extracellular Vesicle Research and Application Areas**
**¼¼Æ÷¿Ü¼ÒÆ÷(EV) ¿¬±¸¡¤ÀÀ¿ë ºÐ¾ßÀÇ ½Å±Ô µ¿Çâ**
* ÁÖÃÖÃø »çÁ¤¿¡ µû¶ó »çÀü ¿¹°í¾øÀÌ ÇÁ·Î±×·¥ÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.>
°ñµå ½ºÆù¼
Àü½Ã±â¾÷
½ºÆù¼¡¤Àü½Ã ±âȸ
ÀÚ¼¼ÇÑ »çÇ×Àº(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀ̼ÇÀ¸·Î ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù.
SelectBIO ÄÁÆÛ·±½º¿¡¼ Àü½Ã/½ºÆù¼·Î Âü°¡ÇÏ´Â ÀÌÀ¯
½ºÆä¼È¸®½ºÆ® : SelectBIO´Â Drug Discovery¿Í »ý¸í°úÇÐ ÄÁÆÛ·±½º¸¦ Àü¹®À¸·Î Çϰí ÀÖ½À´Ï´Ù. SelectBIO ½ºÅÇÀÇ ´Ù¼ö´Â ¹ÙÀÌ¿À»çÀ̾𽺠ÀÚ°ÝÀ» º¸À¯Çϰí ÀÖÀ¸¸ç, ¼ö³â°£ÀÇ °æÇèÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Àü¹® ¿ë¾î·Î ´ëÀÀÇϰí, °í°´ÀÇ ¿ä±¸¸¦ ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
¿ì¼öÇÑ °í°´ ¼ºñ½º : SelectBIOÀÇ ¿µ¾÷ÆÀÀÌ Àü¹®ÀûÀÎ ¾îµå¹ÙÀ̽º ¹× Ä¿½ºÅ͸¶ÀÌÁî ÆÐŰÁö·Î Áö¿øÇÕ´Ï´Ù. °è¾à ÈĺÎÅÍ À̺¥Æ® °³ÃÖÀü¡¤À̺¥Æ® °³ÃÖ Áß¿¡µµ °í°´ ¼ºñ½º ºÎ¹®ÀÌ °í·ÁÇØ¾ß ÇÒ »çÇ×À» ¸ðµÎ ¾Ë·Áµå¸³´Ï´Ù.
Extracellular Vesicles/Exosomes Asia 2025 Conference °³ÃÖÁö
SelectBIO is delighted to host Extracellular Vesicles/Exosomes Asia 2025 Conference at the:
Hotel Nikko Narita
500 Tokko Narita-shi
Chiba 286-0106
Japan
Telephone: +81-476-32-0032
-
The Hotel Nikko Narita is very easily accessible from international destinations via Tokyo Narita International Airport (Airport Code: NRT).
-
The hotel can be accessed easily from Narita International Airport via a complimentary bus, usually around 10-15 minutes to and from the airport, depending on terminal chosen.
-
Distance-wise airport to the hotel is approximately 3 kilometers (1.8 miles).
-
If you are arriving to Narita Terminal 1, the shuttle to the hotel stops at bus stop # 16.
-
If you are arriving to Narita Terminal 2, the shuttle to the hotel stops at bus stop # 33.
Guests can make hotel bookings as well as see the different room types on the hotel website.
The hotel website with details is at the link below.




For any hotel reservation-related issues, or if you need any help with hotel bookings, please contact us.
SelectBIO has NOT authorized ANY third party company to assist in hotel bookings or reservations for the conference. Please do NOT do business with any third party companies. If in doubt, please contact us immediately to clarify.
¼îÆ®ÄÚ½º/Æ®·¹ÀÌ´× ÄÚ½º
3D-Printing of Microfluidics
¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ¿ªÇÐ 3D ÇÁ¸°ÆÃ
2025³â 10¿ù 1ÀÏ 19:30 - 21:30
TSURU(È£ÅÚ ´ÖÄÚ ³ª¸®Å¸)

Noah Malmstadt, Professor of Chemical Engineering and Materials Science, University of Southern California
3D ÇÁ¸°ÆÃÀº º¹ÀâÇÑ Ã¤³Î ±¸Á¶¸¦ °¡Áø ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º µð¹ÙÀ̽º¸¦ 3D·Î ½Å¼ÓÈ÷ Á¦Á¶ÇÏ´Â ¹æ¹ýÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù.
ÀÌ ¼îÆ®ÄÚ½ºÀÇ ³»¿ë :
¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º Á¦ÀÛ¿¡ Àû¿ëµÇ´Â 3D ÇÁ¸°ÆÃ ±â¼úÀÇ ¸ÞÄ¿´ÏÁò
¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ÇÁ¸°ÆÃÀÇ »ó¾÷Ȱ¡ °¡´ÉÇÑ Ãֽмַç¼Ç
3D ÇÁ¸°Æ¼µå ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ½Ã½ºÅÛÀÇ ¾ÖÇø®ÄÉÀ̼ǰú ÇѰè
½Å±Ô ±â¼ú°ú ¹Ì·¡ ±â¼úÀÌ ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º Á¦ÀÛ Åø·Î¼ 3D ÇÁ¸°ÆÃÀÇ °¡´É¼ºÀ» ¾î¶»°Ô Çâ»ó½Ã۴°¡?
* ÁÖÃÖÃø »çÁ¤¿¡ µû¶ó »çÀü ¿¹°í¾øÀÌ ÇÁ·Î±×·¥ÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.